Targeting IL-5 could improve outcomes and have steroid-sparing effects in the management of eosinophilic granulomatosis with polyangiitis. However, some questions remain about how this approach affects specific aspects of the disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long-term mepolizumab treatment reduces relapse rates in super-responders with eosinophilic granulomatosis with polyangiitis
Allergy, Asthma & Clinical Immunology Open Access 13 May 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Comarmond, C. et al. Eosinophilic granulomatosis with polyangiitis (Churg Strauss). Clinical characteristics and long term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 65, 270–281 (2013).
Sarnes, E. et al. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin. Ther. 33, 1413–1432 (2011).
Khoury, P., Grayson, P. C. & Klion, A. D. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat. Rev. Rheumatol. 10, 474–483 (2014).
Jakiela, B. et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients. Rheumatology (Oxford) 51, 1887–1893 (2012).
Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198–1207 (2014).
Wechsler, M. E. et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N. Engl. J. Med. 376, 1921–1932 (2017).
Groh, M. et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur. J. Intern. Med. 26, 545–553 (2015).
Sablé-Fourtassou, R. et al. Antineutrophil cytoplasmic antibodies and the Churg–Strauss syndrome. Ann. Intern. Med. 143, 632–638 (2005).
Smith, K. Genetic studies in ANCA-associated vasculitis point to a new, practical disease classification based on autoantibody specificity. Presented at the 18th International Vasculitis and ANCA Workshop, Tokyo, Japan. Rheumatology (Oxford) 56 (Suppl. S3), iii3 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Guillevin, L. Mepolizumab for eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol 13, 518–519 (2017). https://doi.org/10.1038/nrrheum.2017.117
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.117
